<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589652</url>
  </required_header>
  <id_info>
    <org_study_id>81271833</org_study_id>
    <nct_id>NCT02589652</nct_id>
  </id_info>
  <brief_title>Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy</brief_title>
  <official_title>Efficacy of Switch or Sequential Combination Therapy of Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Low HBsAg and HBeAg Titers After Long-term Entecavir Therapy: A Multicenter, Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective cohort study to evaluate the efficacy and safety of
      sequential combination or switch therapy of pegylated interferon alfa-2a in chronic hepatitis
      B patients with low HBsAg and HBeAg titers after long-term entecavir therapy, and compared to
      those who continued on ETV therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B (CHB) infection remains a global health treat. The ideal end point of
      therapy is HBsAg loss or HBsAg seroconversion, indicating a complete remission of CHB. In
      patients with HBeAg-positive CHB, sustained HBeAg seroconversion is also a desirable end
      point. Current therapies include pegylated interferon (PegIFN) finite and nucleos(t)ide
      analogues (NUCs) longterm therapy. However, only 30-40% of patients may achieve HBeAg
      seroconversion on PegIFN monotherapy, whereas 15-20% of patients on entecavir (ETV).
      Recently, accumulating evidence had shown that optimization of switching or combining PegIFN
      in patients on long-term ETV therapy may increase rate of HBeAg seroconversion and even lead
      to the complete eradication of HBV. However, these two regimens has not been tested
      adequately in patients with low HBsAg/HBeAg titers on long-term ETV therapy.

      This is a multicenter, prospective cohort study to evaluate the efficacy and safety of
      sequential combination or switch therapy of pegylated interferon alfa-2a in chronic hepatitis
      B patients with low HBsAg and HBeAg titers after long-term entecavir therapy, and compared to
      those who continued on ETV therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of HBeAg seroconversion</measure>
    <time_frame>week 72 (24 weeks after 48 weeks of treatment)</time_frame>
    <description>Loss of HBeAg and detection of anti-HBe antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of HBsAg loss</measure>
    <time_frame>week 72 (24 weeks after 48 weeks of treatment)</time_frame>
    <description>HBsAg loss with or without detection of anti-HBs antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBV DNA &lt;20IU/mL</measure>
    <time_frame>week 72 (24 weeks after 48 weeks of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBsAg seroconversion</measure>
    <time_frame>week 72 (24 weeks after 48 weeks of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching a ≥ 1log10 decline of quantitative HBsAg</measure>
    <time_frame>week 72 (24 weeks after 48 weeks of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline of quantitative HBsAg from baseline</measure>
    <time_frame>week 72 (24 weeks after 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Switch group</arm_group_label>
    <description>Patients who have been assigned to pegylated interferon alfa-2a.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential combination group (S-C group)</arm_group_label>
    <description>Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETV group</arm_group_label>
    <description>Patients who have been assigned to entecavir monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a</intervention_name>
    <description>ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks</description>
    <arm_group_label>Switch group</arm_group_label>
    <other_name>PegIFN alpha-2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus Entecavir</intervention_name>
    <description>ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks</description>
    <arm_group_label>Sequential combination group (S-C group)</arm_group_label>
    <other_name>PegIFN alpha-2a</other_name>
    <other_name>ETV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>ETV 0.5mg oral daily for 48 weeks</description>
    <arm_group_label>ETV group</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Hepatitis B Patients with Low HBsAg and HBeAg Titers after Long-term Entecavir
        Therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients &gt; 18 and ≤ 60 years of age;

          -  Positive HBsAg for more than 6 months;

          -  Patients receiving previous ETV therapy ≥2 years;

          -  Patients who have achieved undetectable HBV DNA, HBsAg &lt;1500IU/mL and HBeAg &lt;200S/CO
             prior to switch or S-C therapy;

          -  ALT&lt;=10*ULN and TB&lt;2*ULN;

          -  Patients who have been assigned to treatment with PegIFN (S-C or switch) or continuous
             ETV after previous ETV therapy

        Exclusion Criteria:

          -  Evidence of decompensated cirrhosis or hepatocellular carcinoma;

          -  Serological evidence of co-infection with HCV, HDV or HIV;

          -  Pregnant or breast-feeding women;

          -  Patients with diseases that might contraindicate to PegIFN therapy including severe
             psychiatric diseases, immunological diseases, severe retinopathy, thyroid dysfunction,
             leukocytopenia, thrombopenia, etc

          -  Patients receiving concomitant therapy with telbivudine;

          -  A history of drug or alcohol abuse;

          -  Other conditions that investigates consider not suitable for participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenhong Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiqi Yu, MD</last_name>
    <phone>+86 21 52888123</phone>
    <phone_ext>8123</phone_ext>
    <email>07301010205@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenhong Zhang, MD, PhD</last_name>
    <phone>+86 21 52889999</phone>
    <phone_ext>8123</phone_ext>
    <email>zhangwenhong@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiabin Li</last_name>
      <email>lijiabin9441@vip.sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufeng Gao</last_name>
      <email>aygyf@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yao Xie</last_name>
      <email>xieyao@public.bta.net.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou Municipal Infectious Disease Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minghua Lin</last_name>
      <email>fulmh@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan No.2 People's Hospital, Zhongshan, Guangdong</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The third People's Hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Yuan</last_name>
      <email>13500054798@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caiyan Zhao</last_name>
      <email>zhaoy2005@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fifth People's Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuanwu Zhu</last_name>
      <email>zhuchw@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuebing Yan</last_name>
      <email>yxbxuzhou@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenyang Municipal Infectious Disease Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingxiang Zhang</last_name>
      <email>zmx6511@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanhua Ren</last_name>
      <email>ganbingzx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Medical School of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingren Zhao</last_name>
      <email>zhaoyingren@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Luzhou Medical College</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <zip>646000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gang Wu</last_name>
      <phone>0830-2292040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Sichuan</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xingxiang Yang</last_name>
      <email>xxyang508@tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaowei Xu</last_name>
      <email>xxw69@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Yinzhou of Ningbo</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guojun Li</last_name>
      <email>13615880689@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rui'an People's Hospital</name>
      <address>
        <city>Rui'an</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liang Hong</last_name>
      <phone>0577-65866555</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>Director of Division of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Pegylated interferon</keyword>
  <keyword>Entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

